CD274 and salivary gland carcinoma: Upon analysis of a cohort of 109 advanced salivary gland carcinomas from the KEYNOTE-158 trial, pembrolizumab had an objective response rate of 4.6% in the overall population and 10.7% in the PD-L1 positive (CPS ≥ 1) cohort.